Gráfica de Acción Histórica
6 Meses : De Nov 2018 a May 2019
By Josh Beckerman
A diabetes drug being developed by Sanofi (SNY) and Lexicon Pharmaceuticals Inc. (LXRX) received a tie vote from a U.S. Food and Drug Administration advisory panel.
Before the 8-8 vote, Lexicon shares had been halted all day.
The FDA isn't required to follow the advice of such advisory panels, but it generally does so. An FDA decision is expected by March 22.
Write to Josh Beckerman at email@example.com
(END) Dow Jones Newswires
January 17, 2019 19:12 ET (00:12 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.